News und Analysen
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses
Lonza Delivers a Strong Q3 2025 and Confirms Full-Year 2025 Outlook for its CDMO and CHI Businesses
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
Bayer will present methods and baseline characteristic data from the global Phase III OCEANIC-STROKE study with the investigational agent asundexian, in a late-breaking presentation at the upcoming
Sonova expands AI leadership with innovations debuting at EUHA 2025
Sonova expands AI leadership with innovations debuting at
EUHA 2025
EQS-News: Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
EQS-News: Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-Adhoc: Pulsion Medical Systems SE: MAQUET Medical Systems AG increases the amount of the cash compensation for the transfer of the shares in Pulsion Medical Systems SE to be EUR 20,67
EQS-Adhoc: Pulsion Medical Systems SE: MAQUET Medical Systems AG increases the amount of the cash compensation for the transfer of the shares in Pulsion Medical Systems SE to be EUR 20,67
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
EQS-Adhoc: M1 Kliniken AG: M1 Kliniken AG: HAEMATO AG sells its 100% subsidiary HAEMATO Pharm GmbH to PHOENIX group
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare group PLC
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare group PLC
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest and the only ForwardFarm
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, today announced positive 36-month data from exPDite, a Phase I
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
EQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies